 | |
| Clinical data | |
|---|---|
| Other names | TAK-925 |
|
Routes of administration | Intravenous [1] [2] |
| Drug class | Orexin receptor agonist |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| PDB ligand | |
| CompTox Dashboard ( EPA) | |
| Chemical and physical data | |
| Formula | C21H32N2O5S |
| Molar mass | 424.56 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
Danavorexton (developmental code name TAK-925) is a selective orexin 2 receptor agonist. [1] It is a small-molecule compound and is administered intravenously. [1] [2] The compound was found to dose-dependently produce wakefulness to a similar degree as modafinil in a phase 1 clinical trial. [1] [3] As of March 2021, danavorexton is under development for the treatment of narcolepsy, idiopathic hypersomnia, and sleep apnea. [2] [1] [4] It is related to another orexin receptor agonist, firazorexton (TAK-994), the development of which was discontinued for safety reasons in October 2021. [1] [5]
See also
References
- ^ a b c d e f Jacobson LH, Hoyer D, de Lecea L (January 2022). "Hypocretins (orexins): The ultimate translational neuropeptides". J Intern Med. 291 (5): 533–556. doi: 10.1111/joim.13406. PMID 35043499. S2CID 248119793.
- ^ a b c "Danavorexton - Takeda". Adis Insight. Springer Nature Switzerland AG. Retrieved 7 March 2021.
- ^ Evans, R., Hazel, J., Faessel, H., Wu, J., Hang, Y., Alexander, R., ... & Hartman, D. (2019). Results of a phase 1, 4-period crossover, placebo-controlled, randomized, single dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-925, a novel orexin 2 receptor agonist, in sleep-deprived healthy adults, utilizing modafinil as an active comparator. Sleep Medicine, 64, S106. https://scholar.google.com/scholar?cluster=10933819770107034612
- ^ Evans R, Tanaka S, Tanaka S, Touno S, Shimizu K, Sakui S, et al. (December 2019). "A Phase 1 single ascending dose study of a novel orexin 2 receptor agonist, TAK-925, in healthy volunteers (HV) and subjects with narcolepsy type 1 (NT1) to assess safety, tolerability, pharmacokinetics, and pharmacodynamic outcomes". Sleep Medicine. 64: S105–S106. doi: 10.1016/j.sleep.2019.11.290. S2CID 213696542.
- ^ Tong A (6 October 2021). "Takeda flashes red light on 'breakthrough' narcolepsy drug after PhII trials turned up mysterious safety signal". Endpoints News.
External links
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
|
| |
| Clinical data | |
|---|---|
| Other names | TAK-925 |
|
Routes of administration | Intravenous [1] [2] |
| Drug class | Orexin receptor agonist |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| PDB ligand | |
| CompTox Dashboard ( EPA) | |
| Chemical and physical data | |
| Formula | C21H32N2O5S |
| Molar mass | 424.56 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
Danavorexton (developmental code name TAK-925) is a selective orexin 2 receptor agonist. [1] It is a small-molecule compound and is administered intravenously. [1] [2] The compound was found to dose-dependently produce wakefulness to a similar degree as modafinil in a phase 1 clinical trial. [1] [3] As of March 2021, danavorexton is under development for the treatment of narcolepsy, idiopathic hypersomnia, and sleep apnea. [2] [1] [4] It is related to another orexin receptor agonist, firazorexton (TAK-994), the development of which was discontinued for safety reasons in October 2021. [1] [5]
See also
References
- ^ a b c d e f Jacobson LH, Hoyer D, de Lecea L (January 2022). "Hypocretins (orexins): The ultimate translational neuropeptides". J Intern Med. 291 (5): 533–556. doi: 10.1111/joim.13406. PMID 35043499. S2CID 248119793.
- ^ a b c "Danavorexton - Takeda". Adis Insight. Springer Nature Switzerland AG. Retrieved 7 March 2021.
- ^ Evans, R., Hazel, J., Faessel, H., Wu, J., Hang, Y., Alexander, R., ... & Hartman, D. (2019). Results of a phase 1, 4-period crossover, placebo-controlled, randomized, single dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-925, a novel orexin 2 receptor agonist, in sleep-deprived healthy adults, utilizing modafinil as an active comparator. Sleep Medicine, 64, S106. https://scholar.google.com/scholar?cluster=10933819770107034612
- ^ Evans R, Tanaka S, Tanaka S, Touno S, Shimizu K, Sakui S, et al. (December 2019). "A Phase 1 single ascending dose study of a novel orexin 2 receptor agonist, TAK-925, in healthy volunteers (HV) and subjects with narcolepsy type 1 (NT1) to assess safety, tolerability, pharmacokinetics, and pharmacodynamic outcomes". Sleep Medicine. 64: S105–S106. doi: 10.1016/j.sleep.2019.11.290. S2CID 213696542.
- ^ Tong A (6 October 2021). "Takeda flashes red light on 'breakthrough' narcolepsy drug after PhII trials turned up mysterious safety signal". Endpoints News.
External links
|
| This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |